SciELO - Scientific Electronic Library Online

 
vol.30 número1Complicaciones y mortalidad de la cirugía de resección pulmonar en unidades de medicina intensivaUso de rituximab en trombocitopenia inmune: experiencia en el Hospital de Clínicas índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Links relacionados

Compartilhar


Revista Médica del Uruguay

versão On-line ISSN 1688-0390

Resumo

DUFORT, Gustavo et al. Trasplante alogénico haploidéntico de progenitores hematopoyéticos en pediatría en Uruguay. Rev. Méd. Urug. [online]. 2014, vol.30, n.1, pp.17-29. ISSN 1688-0390.

Abstract Introduction: allogenic hematopoietic stem cell transplantation (HSCT) is the only currently available curative treatment for a number of high-risk hematologic malignancies and for a range of inherited and acquired non-malignant diseases. Haploidentical (HI) HSCT is a valid option for patients who lack an HLA-identical brother. Objective: to describe the results obtained with HI HSCT in pediatrics. Method: in 2005 an HI HSCT program was started at the Pediatric Hemato-Oncological Department of the Centro Hospitalario Pereira Rossell, for patients who lack an HLA-matched related donor. Results: Thirty two patients were transplanted, 24 of them with hematological malignancies and 8 with non-malignant diseases. Two strategies were used to prevent the Graft-Versus-Host-Disease (GVHD), in- vitro T-cell depletion (28 patients) and in-vivo depletion of aloreactives T-cells with high-dose post-transplantation cyclophosphamide (4 patients). Successful engraftment occurred in 27 patients (84%), with full-donor chimerism. Incidence of acute and chronic GVHD was 26.9% and 11.8% respectively. One year non-relapsed mortality was 21.9%. With a median follow-up of 32 months, the overall survival was 52.4%. Conclusions: HI HSCT has proved to be a feasible option in our country for those patients without an HLA-identical donor. The results obtained are comparable to those obtained with other alternative donors and costs are more reasonable. Today, Uruguay is in a better position to offer a HSCT to patients who need it.

Palavras-chave : TRANSPLANTATION, HOMOLOGOUS; HAPLOIDE; HEMATOPOIETIC STEM CELLS.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons